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Introduction: Mesenchymal stem cells (MSCs) transplantation has been demonstrated to be an effective strategy
for the treatment of cardiovascular disease. However, the low survival rate of MSCs at local diseased tissue reduces
the therapeutic efficacy. We therefore investigated the influence of MicroRNA-378 (miR-378) transfection on MSCs
survival and vascularization under hypoxic-ischemic condition in vitro.
Methods: MSCs were isolated from bone marrow of Sprague–Dawley rats and cultured in vitro. The third passage of
MSCs were divided into the miR-378 group and control group. For the miR-378 group, cells were transfected with
miR-378 mimic. Both groups experienced exposure to hypoxia (1% O2) and serum deprivation for 24 hours, using
normoxia (20% O2) as a negative control during the process. After 24 hours of reoxygenation (20% O2), cell proliferation
and apoptosis were evaluated. Expressions of apoptosis and angiogenesis related genes were detected. Both groups
were further co-cultured with human umbilical vein endothelial cells to promote vascular differentiation for another
6 hours. Vascular density was assessed thereafter.
Results: Compared with the control group, MSCs transfected with miR-378 showed more rapid growth. Their proliferation
rates were much higher at 72 h and 96 h under hypoxic condition (257.33% versus 246.67%, P <0.01; 406.84% versus
365.39%, P <0.05). Cell apoptosis percentage in the miR-378 group was significantly declined under normoxic and hypoxic
condition (0.30 ± 0.10% versus 0.50 ± 0.10%, P <0.05; 0.60 ± 0.40% versus 1.70 ± 0.20%, P <0.01). The miR-378 group formed
a larger number of vascular branches on matrigel. BCL2 level was decreased accompanied with an upregulated
expression of BAX in the two experimental groups under the hypoxic environment. BAX expression was reduced in the
miR-378 group under the hypoxic environment. In the miR-378 group, there was a decreased expression of tumor
necrosis factor-α on protein level and a reduction of TUSC-2 under normoxic environment. Their expressions were both
downregulated under hypoxic environment. For the angiogenesis related genes, enhanced expressions of vascular
endothelial growth factorα, platelet derived growth factor-β and transforming growth factor-β1 could be detected both
in normoxic and hypoxic-ischemic conditions.
Conclusion: MiR-378 transfection could effectively promote MSCs survival and vascularization under hypoxic-ischemic
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Cardiovascular disease with resultant heart failure and ma-
lignant arrhythmia is a major cause of morbidity and mor-
tality worldwide [1]. In recent years, stem cell therapy has
emerged as a novel strategy for the treatment of cardiovas-
cular disease, and its beneficial efficacies have been con-
firmed by various preclinical and clinical trials [2-5]. Bone
marrow mesenchymal stem cells (MSCs), which have great
potential for proliferation and differentiation, have the cap-
acity to differentiate into cardiomyocytes and vascular cells
under appropriate conditions [6,7]. Implantation of MSCs
results in regeneration of cardiomyocytes and neovasculari-
zation in myocardial infarction. Moreover, these cells can
confer protection to ischemic tissues through the release of
paracrine factors, thus providing a promising therapeutic
modality for repair of the injured heart [8-10]. A series of
clinical trials have already shown that MSCs treatment can
attenuate ventricular remodeling and improve cardiac func-
tion in patients with myocardial infarction and chronic
heart failure [4,5,11,12]. However, inferior survival of MSCs
under hypoxic condition reduces their therapeutic efficacy
[13,14]. Low survival rates of the donor cells could be due
to inflammation, ischemia and apoptosis [15,16]. Therefore,
how to enhance MSCs survival and promote their
vascularization in the local hypoxic environment becomes a
main issue that needs to be addressed in order to improve
the clinical benefits of MSCs transplantation.
microRNAs (miRNAs) are small noncoding RNAs
that control gene expression post-transcriptionally.
They exert functions over a wide range of cellular pro-
cesses, including the regulation of stem cell pluripo-
tency and differentiation [17]. Manipulation of miRNAs
in stem cells may enhance their capacity for cell survival
and vascular regeneration [18,19]. miRNAs can promote
MSCs differentiation into cardiovascular cell lineage and
affect MSCs-mediated cardiac repair [20]. microRNA-378
(miR-378) is a specific miRNA that can induce angio-
genesis in tumors [21]. Experimental studies show that
miR-378 transfection significantly enhances cell viability
and inhibits cell apoptosis [22,23]. In addition, miR-378 is
a newly described member of the cardiac-enriched miR-
NAs modulating cardiac growth during the postnatal
period [24]. Its deficiency leads to the development of car-
diac hypertrophy [25]. A distinct reduction of miR-378 in
patients with heart failure has been reported, implying that
it may also participate in the disease progression of heart
failure [26].
miR-378 is closely associated with stem cell survival
and vascular differentiation. In this study, MSCs were
transfected with miR-378 and exposed to normal and
hypoxic–ischemic conditions to observe their survival,
proliferation and apoptosis. Vascular density was evalu-
ated and the expression of molecules related to apop-
tosis and vasculogenesis was detected.Materials and methods
Ethics statement
One-month-old Sprague–Dawley rats were obtained
from the Animal Experimental Center of the Sun
Yat-sen University (Guangzhou, China). All animal
handling and procedures were performed in accordance
with protocols approved by the Animal Ethics Commit-
tee of Sun Yat-sen University (201210016).
Isolation and culture of bone marrow mesenchymal
stem cells
Bone marrow cells were collected from 1-month-old
Sprague–Dawley rats by flushing femurs and tibias under
sterile conditions. The cells were then cultured (37°C, 5%
carbon dioxide) in 25 cm2 culture flasks with complete cul-
ture medium supplemented with 10% fetal bovine serum
penicillin (100 IU/ml) and streptomycin (100 μg/ml). On
the third day of culture, the medium was replaced and non-
adherent cells were removed. Adherent cells gaining 90%
confluence were passaged using 0.25% trypsin–ethylenedi-
amine tetraacetic acid (Mediatech, Hendon, VA, USA) and
then maintained in complete medium. Characteristics of
MSCs were identified by fluorescence-activated cell sorting
as reported previously [27].
microRNA-378 transfection
miR-378 mimic (mature sequence rno-miR-378a-5p: 4-
cuccugacuccagguccugugu-25) was synthesized and provided
by Ruibo Biotechnology Corporation (Guangzhou, China).
To obtain MSCs overexpressing miR-378 effectively, third-
passage MSCs were transfected with miR-378 mimic using
Lipofectamine™ 2000 (catalogue number 11668019; Invitro-
gen, Carlsbad, California, USA) according to the manufac-
turer’s instructions. Opti-MEM (catalogue number 31985070;
Invitrogen) was applied as transfection medium and the
medium was changed 4 hours after transfection. Total RNA
and cell lysate were collected for the indicated assays.
Hypoxia/reoxygenation treatments of MSCs
Twenty-four hours after transfection, cells of the miR-378
group (MSCs transfected with miR-378) and the control
group (MSCs without transfection) were both incubated in
serum-free media with 1% oxygen in a Galaxy® 48 R incuba-
tor (Eppendorf/Galaxy Corporation, Connecticut, USA) at
37°C for 24 hours and then exposed to normoxic conditions
(20% oxygen) for another 24 hours. Normoxia was used as
negative control during the experiments for the two groups.
Survival and apoptosis evaluation of MSCs
After the above treatments, the MSCs of different groups
were collected and suspended in complete culture medium.
The growth curve and MTS assay (cellTiter96AQ, one
solution cell proliferation assay, catalogue number G3582;
Promega, Madison, Wisconsin, USA) were adopted to
Xing et al. Stem Cell Research & Therapy 2014, 5:130 Page 3 of 10
http://stemcellres.com/content/5/6/130evaluate survival and proliferation ability of MSCs. A total
of 1 × 105 cells were equally seeded into each well on 96-
well plates. After 24 hours of preconditioning, MTS was
added to the medium at a final concentration of 0.5 mg/ml
for 4 hours. Results were read from cellTiter96AQ at differ-
ent time points (24, 48, 72 and 96 hours) respectively.
The terminal deoxynucleotidyl transferase biotin-dUPT
nick end-labeling assay was applied for assessing MSC
death and apoptosis in vitro after 24 hours of reoxygena-
tion. Cell slices were fixed in 10% formaldehyde for
15 minutes and pretreated with 0.2% Triton X-100 for 15 mi-
nutes. The slices were then infiltrated in an equilibration
buffer followed by incubating with terminal deoxynucleoti-
dyl transferase enzyme and a nucleotide mix for another
75 minutes. All sections were examined under a florescent
microscope (DMI6000B; Leica, Brunswick, Germany).
Vascular networks formation assay of MSCs
Aliquots of human umbilical vein endothelial cells (Yiyuan
Biotechnology Corporation, Guangzhou, China) were
seeded onto matrigel-coated wells (catalogue number
356234; BD Corporation, New York, USA) of a 24-well
plate. After hypoxia/reoxygenation treatments, MSCs were
then cocultured with human umbilical vein endothelial cells
in 1% fetal calf serum-supplemented Dulbecco’s modified
Eagle’s medium (catalogue number SH30021.01B; Hyclone,
Logan City, Utah, USA). After incubating at 37°C for
6 hours, vascular network formation was examined by a
phase-contrast microscopy (CKX41, U-CTR30-2; Olympus,
Tokyo, Japan), and the number of the vascular branches
was quantified by randomly selecting five fields per well as
described previously [28].
Western blot analysis
Protein levels of BCL2, BAX, tumor necrosis factor alpha
(TNFα), TUSC-2, vascular endothelial growth factor
(VEGF) alpha, platelet-derived growth factor (PDGF) beta
and transforming growth factor beta-1 (TGFβ1) were
measured by western blot. After 24 hours of reoxygena-
tion, MSCs were washed several times with phosphate-
buffered saline before collection and lysing with modified
RIPA buffer. Cells were completely lysed after repeated
vortexing and supernatants were acquired though centri-
fugation at 14,000 × g for 20 minutes. Proteins were then
resolved by SDS-PAGE and subsequently transferred
to a polyvinylidenedifluoride membrane (IPVH00010;
Millipore, Boston, MA, USA) before incubating with pri-
mary antibodies overnight at 4°C. The membranes were
subjected to three 5-minute washes with Tris-buffered
saline–Tween and then incubated with anti-IgG horserad-
ish peroxidase-conjugated secondary antibody (Southern
Biotech, Birmingham, Alabama, USA) for 60 minutes at
room temperature. After extensive washing, bands were
detected by enhanced chemiluminescence. The bandintensities were quantified using image software (image
J 2×, version 2.1.4.7).
Quantitative real-time polymerase chain reaction
Total RNA was isolated from MSCs with hypoxia/reoxy-
genation treatments using a Trizol reagent (Invitrogen)
followed by digestion with RNase-free DNase (Promega).
The concentration and integrity of total RNA were esti-
mated and the real-time polymerase chain reaction (RT-
PCR) was conducted on an ABI PRISM® 7500 Sequence
Detection System using SYBR Green qPCR SuperMix
(Invitrogen). The primers are described in Table 1. Spe-
cific products were amplified and detected at 95°C for
10 minutes, followed by 40 cycles at 95°C for 15 seconds,
and at 60°C for 30 seconds, at which point data were ac-
quired. The miR-378 expression level was quantified using
probes for miR-378 and U6 RNA (internal control). The
relative level of miRNA was calculated using the 2−ΔΔCt
method. For the assays of the molecules examined, the re-
sults were quantified as the threshold cycle of each target
gene and normalized into the ΔCt value. Quantifications
of fold-change in gene expressions were also performed
using the 2−ΔΔCt method.
Statistical analysis
All quantitative data are described as mean ± standard de-
viation. The significance of differences among groups was
determined by analysis of variance and Scheffe’s multiple-
comparison techniques. Comparisons between time-based
measurements within each group were performed with
analysis of variance for repeated measurements. P <0.05
was considered statistically significant.
Results
Mesenchymal stem cells survival was enhanced post
transfection of miR-378
miR-378 expression status after transfection with miR-378
mimic was confirmed by quantitative RT-PCR (P < 0.01;
Figure 1A) The two experimental groups presented a lower
growth and proliferation rate under a hypoxic environment
at 72 hours and 96 hours, while both groups showed a
higher inhibition rate in this condition (P < 0.01; Figure 1B,
C, D). The miR-378 group displayed a more rapid growth
under hypoxic environment at 72 hours and 96 hours in
contrast with the control group (0.78 ± 0.02 vs. 0.73 ± 0.02,
P < 0.05; 1.22 ± 0.03 vs. 1.08 ± 0.03, P < 0.05) (Figure 1B).
Moreover, the transfected cells had a higher proliferation
rate (257.33% vs. 246.67%, P < 0.01; 406.84% vs. 365.39%, P
< 0.05) (Figure 1C). The inhibition rate of the miR-378
group was lower under a hypoxic environment at 72 hours
and 96 hours (3.73% vs. 9.47%, P < 0.01; 1.63% vs. 13.60%,
P < 0.01) (Figure 1D), indicating that miR-378 could
alleviate the inhibition of MSC proliferation induced by
hypoxia–ischemia.
Table 1 Primers for quantitative real-time polymerase chain reaction









PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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miR-378 transfection
The two groups both exhibited a higher apoptosis rate
under the hypoxic environment (0.50 ± 0.10% vs. 1.7 ±
0.20%, P < 0.01; 0.30 ± 0.10% vs. 0.60 ± 0.40%, P < 0.01)
(Figure 2B). Compared with the control group, terminal
deoxynucleotidyl transferase biotin-dUPT nick end-
labeling staining showed that the apoptosis rate
of the miR-378 group was significantly decreased
under normal (0.30 ± 0.10% vs. 0.50 ± 0.10%, P < 0.05;
Figure 2A, B) and hypoxic (0.60 ± 0.40% vs. 1.70 ±
0.20%, P < 0.01; Figure 2A, B) environments.Figure 1 Mesenchymal stem cell proliferation after the transfection of mic
(miRNA) mimic detected by quantitative real-time polymerase chain reaction. (B)
(cellTiter96AQ, one solution cell proliferation assay, catalogue number G3582; Pro
rate = optical density (OD) values at other time points divided by OD value at the
divided by native MSC group OD value) × 100% (same time). Native MSCs, MSCs
in normoxic conditions; MSCs + hypoxia, MSCs cultured in hypoxic conditions; mAngiogenesis ability of MSCs was promoted after miR-378
transfection
Once cocultured with human umbilical vein endothelial
cells, MSCs transfected with miR-378 formed a larger
number of vascular branches on matrigel. Under nor-
moxic conditions, the numbers of vascular branches in
the miR-378 group were obviously higher than in the
control group (17.50 ± 0.55 vs. 15.17 ± 1.17, P < 0.01).
The same phenomenon could be observed when the two
groups of cells were exposed to a hypoxic–ischemic
environment (18.00 ± 1.79 vs. 14.67 ± 1.03, P < 0.01)
(Figure 3).roRNA-378. (A)miR-378 expression status after transfection with microRNA
Mesenchymal stem cell (MSC) proliferation rate tested by MTS assay
mega, Madison, Wisconsin, USA). *P<0.05; **P< 0.01. (C) Proliferation
beginning × 100% (same sample). (D) Inhibition rate = (1 – OD value
cultured in normoxic conditions; miR-378, miR-378-transfected MSCs cultured
iR-378 + hypoxia, miR-378-transfected MSCs cultured in hypoxic conditions.
Figure 2 microRNA-378 transfection reduced hypoxia-induced apoptosis in mesenchymal stem cells. (A) Apoptosis of mesenchymal stem
cells (MSCs) was detected and assessed by terminal deoxynucleotidyl transferase biotin-dUPT nick end-labeling (TUNEL) staining. lane a, DAPIr staining
localization; lane b, TUNEL staining; lane c, overlap figure of lanes a and b. (B) Comparison of apoptotic rates between groups after miR-378
transfection in normoxic and hypoxic environments. *P < 0.05, **P < 0.01. Native MSCs, MSCs cultured in normoxic conditions; miR-378, miR-378-
transfected MSCs cultured in normoxic conditions; MSCs + hypoxia, MSCs cultured in hypoxic conditions; miR-378 + hypoxia, miR-378-transfected
MSCs cultured in hypoxic conditions.
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after miR-378 transfection
The expression of apoptosis-related genes was examined
by western blot and quantitative RT-PCR in both groups
after cells experienced hypoxia/reoxygenation or were ex-
posed to normoxic (20% oxygen) conditions (Figure 4).
Detection of the BCL2 family proteins showed that the
BCL2 level was decreased, accompanied with an elevated
expression of BAX in the two experimental groups under
a hypoxic environment (Figure 4A, C, D). There was no
difference of the expression of BCL2 between the miR-378Figure 3 microRNA-378 promoted the angiogenesis ability of mesenc
between the two experimental groups in normoxic and hypoxic condition
(magnification × 100): (a) native MSCs, MSCs cultured in normoxia condition
conditions; (c) MSCs + hypoxia, MSCs cultured in hypoxic conditions; (d) mi
conditions. (B) Comparison of the numbers of vascular branches betweengroup and the control group under normoxic and hypoxic
environments (Figure 4A, C), whereas BAX expression was
reduced in the miR-378 group under a hypoxic environment
(Figure 4A, D). The TNFα level was increased under the
hypoxic environment in the two groups (Figure 4B, E). In
the miR-378 group, TNFα protein expression was decreased
under the normoxic environment (Figure 4B) and its expres-
sion was downregulated both on mRNA and protein level in
hypoxic conditions (Figure 4B, E). TUSC-2 expression was
enhanced on the protein level under a hypoxic environment
in the two groups (Figure 4B). Its level was downregulatedhymal stem cells. Comparison of the numbers of vascular branches
s in vitro. (A) Vascular formation of the different groups in vitro
s; (b) miR-378, miR-378-transfected MSCs cultured in normoxia
R-378 + hypoxia, miR-378-transfected MSCs cultured in hypoxic
groups. **P < 0.01, transfected versus nontransfected MSCs.
Figure 4 microRNA-378 decreased the expressions of apoptosis-related genes. Changes of apoptosis-related genes under different
conditions in the two experimental groups. Western blot analysis (A), (B) and quantitative real-time polymerase chain reaction (C), (D), (E),
(F) were performed to explore the expressions of BCL-2, BAX, tumor necrosis factor alpha (TNFα) and TUSC-2 after cells of the two experimental
groups were exposed to different conditions. **P < 0.01. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; miRNA, microRNA; MSC,
mesenchymal stem cell.
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under normoxic and hypoxic environments (Figure 4B, F).
Expression of angiogenesis-related genes was enhanced
after miR-378 transfection
Angiogenesis-related genes were detected the same way
as described above. The expression of VEGFα, PDGFβ
and TGFβ1 was decreased in the control group under
hypoxic conditions (Figure 5). However, no differences
in their expressions were observed in the miR-378 group
when exposed to the same environment (Figure 5).
Western blot analysis showed that the expression of
VEGFα, PDGFβ and TGFβ1 was increased in miR-378
transfected MSCs under both normoxic and hypoxic
conditions (Figure 5A). Quantitative RT-PCR indicated
that there was an upregulated expression of PDGFβ on
the mRNA level (Figure 5C), whereas no differences
could be discovered in the expressions of VEGFα and
TGFβ1 genetically (Figure 5B, D).
Discussion
The present study demonstrates that MSCs transfected
with miR-378 showed higher viability and a lower apop-
tosis rate under hypoxic–ischemic conditions. Moreover,their capacity for blood vessel formation was improved.
The expression of proapoptosis genes was decreased
whereas angiogenesis-related genes were found to be up-
regulated after miR-378 transfection.
MSCs are multipotent progenitor cells with the poten-
tial to differentiate into various cell types, including cells
of the cardiovascular lineage [7]. MSCs can be easily iso-
lated and expanded in vitro, making them an optimal
therapeutic approach for cardiovascular disease [29]. In
spite of this, the low survival rate of MSCs after trans-
plantation in vivo restricts their therapeutic efficiencies
[13,14]. Studies have indicated that hypoxia and serum
deprivation can lead to poor viability and apoptosis of
MSCs via triggering a strong inflammatory and oxidative
stress reaction and an overproduction of proapoptosis
factors [15,30]. Diverse methods have been applied to
improve MSCs survival under hypoxic and ischemic
conditions [16,31]. miRNAs play a crucial role in cell pro-
liferation, differentiation and apoptosis [17]. It has been
reported that transfection of specific miRNAs enhances
MSCs survival and their capability for lineage differenti-
ation, making them more conducive to the repair of in-
farct injury [32]. Prior studies have demonstrated that
miR-378 facilitates cancer cell migration and promotes
Figure 5 microRNA-378 enhanced the expression of angiogenesis-related genes. Changes of angiogenesis-related genes under different
conditions in the two experimental groups. Western blot analysis (A) and quantitative real-time polymerase chain reaction (B), (C), (D) were performed
to explore the expression of VEGFα, PDGFβ and TGFβ1 after cells of the two experimental groups were exposed to different conditions. *P < 0.05,
**P < 0.01. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; miRNA, microRNA; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor;
TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
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of miR-378 on MSCs survival and proliferation. The
results indicated that MSCs could be efficiently trans-
fected with miR-378 without affecting cells viability. We
found that MSCs viability was attenuated under the hyp-
oxic condition in the two experimental groups. Cells
transfected with miR-378 showed more rapid growth
and a higher proliferation rate after 24 hours of
hypoxia/reoxygenation. Examination of the apoptosis of
MSCs showed that the number of terminal deoxynu-
cleotidyl transferase biotin-dUPT nick end-labeling-
positive cells was significantly decreased in the miR-378
group. In addition, MSCs transfected with miR-378
presented a distinctly lower apoptosis rate compared
with the control group, suggesting that miR-378 might
exert anti-apoptosis roles in a hypoxic–ischemic
environment in vitro.
Evidence has revealed that miR-378 improves cell
survival and inhibits apoptosis via regulation of various
signaling networks and apoptosis-related genes [24].
miR-378 may reduce hydrogen peroxide and hypoxia-
induced cell death by suppressing the expression of IGF-
1R and its downstream AKT signaling cascade [24]. The
proteins of the BCL2 family are well known as key regu-
lators of cell death and apoptosis. Increasing evidence
sustains that BCL2 family members are the targets of
numerous miRNAs [33]. In the present work, we exam-
ined several BCL2 family proteins including BCL2 and
BAX. We found that BCL2 was downregulated while
BAX was upregulated in the two experimental groups
under the condition of hypoxia exposure. In the miR-378 group, there was no alteration of the expression of
BCL2 both under the normoxic and hypoxic conditions,
while the BAX level was decreased in the hypoxic condi-
tion, implying that miR-378 could attenuate the apop-
tosis of MSCs via suppressing the proapoptosis genes of
the BCL2 family. In addition to the BCL2 family, TUSC-
2 (also known as Fus-1) is a potent proapoptotic gene
[34]. The expression of the miR-378/miR-378 hairpin
enhances cell survival through targeting the transcrip-
tion factor SuFu and Fus-1 [21]. Moreover, miR-378 is
capable of reducing the expression of TUSC-2 at the
protein level [21]. TNFα is another pivotal molecule that
initiates the process of MSC apoptosis [35]. TNFα re-
presses the expression of proinflammatory genes by acti-
vating nuclear factor-κB [36]. TNFα can also stimulate
the caspase cascade related to cell apoptosis [37]. In this
study, the expression of TUSC-2 protein was upregu-
lated and the TNFα level was enhanced in the two
groups under hypoxic environments. Both the expres-
sions of TUSC-2 and TNFα were downregulated in miR-
378-transfected MSCs under a hypoxic environment,
implicating that miR-378 may relieve hypoxia-induced
apoptosis via downregulating TUSC-2 and TNFα.
miRNAs can exist in a lineage-specific pattern and
dominate the fate of stem cell differentiation [38]. Sev-
eral miRNAs have already been found to modulate car-
diovascular cell differentiation [20,39]. Previous studies
have confirmed that miR-378 plays an important role in
blood vessel formation [40,41]. In the present study, we
demonstrated that MSCs transfected with miR-378
formed a larger number of vascular branches on
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capability of MSCs differentiation into vascular lineage.
miRNAs most probably control cell fate via regulating
numerous genes and pathways [17,20]. VEGF has been
identified as a predominant mediator of angiogenesis [42].
VEGF hampers post-hypoxic MSC death and improves
MSCs survival and regeneration in hostile environment of
post-ischemic tissues [43,44]. miR-378 is involved in the ex-
pression of VEGF [45]. miR-378 binds to the 3′ untrans-
lated region of VEGF to compete with miR-125a for the
same seed region and strengthens VEGF expression [45]. In
this study, VEGFα expression was found to be declined in
the control group after hypoxia exposure and this alteration
could be mitigated after miR-378 transfection. In addition,
VEGFα expression was increased at the protein level in the
miR-378 group in hypoxic conditions. The abovementioned
results supported that MSCs might strengthen VEGF ex-
pression in the context of hypoxia exposure. PDGF and TG
Fβ1 secreted by MSCs profoundly impact vascularization as
well as proliferation of MSCs [20,46]. We found that the
expression of PDGFβ and TGFβ1 was also downregulated
under hypoxic conditions in the control group; PDGF re-
ceptors can effectively induce MSCs neovascularization
in vivo [47]. When the expression of PDGF is depressed,
pathways associated with angiogenesis of MSCs are corres-
pondingly obstructed [48]. miRNAs modulate PDGF recep-
tor expression upon ligand stimulation through direct
interaction with the 3′ untranslated region of PDGF recep-
tor in cardiomyocytes [49]. In the present work, PDGFβ
was increased in MSCs transfected with miR-378 under
normoxic and hypoxic conditions, indicating that miR-378
might improve PDGF expression in this condition. MSCs
have the potential to differentiate into smooth muscle cells,
which makes them an ideal cell source for the construction
of tissue-engineered vascular grafts [20]. TGFβ1 is a cyto-
kine with versatile functions [50]. This cytokine can induce
smooth muscle markers in MSCs, subsequently driving
MSCs toward a smooth muscle cell phenotype [51]. TGFβ1
signaling has important functions in the regulation of
MSCs at both transcriptional and post-transcriptional levels
[52]. High concentrations of TGFβ1 contribute to the for-
mation of nestin-positive MSC clusters, resulting in shaping
of marrow osteoid islets accompanied by high levels of
angiogenesis [53]. miRNAs have been proved to mediate
TGFβ-induced signaling circuit loops in the pathological
process of human diseases [54]. They regulate TGFβ1 ex-
pression as well as the TGFβ1-induced epithelial–mesen-
chymal transition phenomenon [55,56]. In this study, we
found that miR-378 transfection notably intensified the ex-
pression of TGFβ1, which could play a crucial role in pro-
moting MSC differentiation into blood vessels. It has been
recently reported that crosstalk between PDGFβ and
TGFβ1 pathways is essential for mediating MSC mechanics
and matrix interactions [57]. Both PDGFβ and TGFβ1 werediscovered to be increased in MSCs transfected with miR-
378. Therefore, we inferred that TGFβ1 in combination
with PDGF might further amplify the formation of vascula-
ture in a hypoxic–ischemic environment.
There are some limitations to this study. MSCs without
transfection were applied as the negative control; experi-
ments using scrambled miRNA as a control for the miR-
378 transfection would further be performed to eliminate
nonspecific effects of transfection and make the data more
convincing. As this study was conducted in vitro, the af-
fection of miR-378 on MSCs in vivo is still lacking. How
miR-378 could act on MSCs survival and differentiation in
the injured heart in animal models would be further ex-
plored in our later work. In addition, although several
molecules that might possibly participate in promoting
MSCs survival after miR-378 transfection have been inves-
tigated in this paper, the elaborate downstream signaling
pathways implicated should be searched for in the future
studies in order to clarify the underlying mechanisms of
the biological functions of miR-378.
Conclusions
In summary, this study showed that miR-378 could promote
MSCs survival and the cells’ ability of vascularization under
hypoxic–ischemic conditions in vitro. miR-378 might func-
tion on apoptosis-related and angiogenesis-related genes.
Further explorations of the implications of miR-378 on
MSCs in vivo will provide new mentalities for the treatment
of ischemic heart disease based on MSCs transplantation.
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